Abstract
Chromoblastomycosis is a chronic skin-related neglected tropical disease caused by melanized (dematiaceous) fungi, predominantly from the Fonsecaea and Cladophialophora species. The disease primarily affects individuals in tropical and subtropical areas, especially those engaged in soil-related occupations. Infection typically ensues following the traumatic introduction of fungal elements into the skin through contaminated plant or soil. This disease exhibits a polymorphic clinical picture. Early manifestations include erythematous patches or small papules, which may gradually develop into nodules, verrucous (warty) plaques, tumorous growths, or scarring lesions. These lesions may be associated with itching, localized pain, and the presence of characteristic black dots on the surface. Without timely intervention, lesions can become disfiguring and complicated by disabling tissue fibrosis, secondary infections, lymphedema, and rarely, malignant transformation (squamous cell carcinoma). The global disease burden observation indicates that the prevalence of chromoblastomycosis varies by region, with certain areas in the world reporting higher rates, particularly Latin America, Africa, and Asian countries. However, the true burden is likely underestimated due to clinical underdiagnoses and a lack of a health surveillance system. Diagnosis relies on a combination of clinical suspicion and identification of muriform cells through direct microscopy, histopathological analysis, and fungal culture. Molecular techniques are increasingly used for precise species identification where it is feasible. Treatment strategies depend on the severity and extent of the disease. Mild cases are managed surgically, and advanced-stage infections usually require prolonged antifungal treatment with itraconazole or terbinafine. These two antifungal agents are commonly used to treat this condition, and some observational studies strongly recommend them as effective first-line therapies against chromoblastomycosis. Additionally, refractory chromoblastomycosis often benefits from combination antifungal therapy and adjunctive treatments. Preventive strategies emphasize the use of protective clothing and the avoidance of skin trauma during outdoor work in the most vulnerable or endemic countries. In resource-limited settings, such as Ethiopia and other parts of the world, prevention faces several challenges, including delayed diagnosis, poor treatment adherence, and lack of community awareness, all of which contribute to chronicity, disability, and poor quality of life. To improve outcomes, it is still critical to strengthen early detection, raise community awareness, and make antifungal therapy more accessible. This review summarizes the epidemiology, pathogenesis, diagnosis, treatment, and prognosis of chromoblastomycosis in resource-limited settings to raise awareness or equip healthcare professionals with the knowledge needed to improve early diagnosis and treatment.
Introduction
Chromoblastomycosis (CBM), otherwise known as chromomycosis is an indolent, chronic cutaneous granulomatous fungal infection caused by melanized fungi, primarily from the Herpotrichiellaceae family (, ā). The disease is a long-standing infection that typically occurs after fungal elements are introduced into the skin through trauma, particularly among individuals engaged in agricultural and soil-related activities (). It represents one of the most prevalent subcutaneous mycoses in endemic areas and carries a substantial public health burden (, ) because of causing progressive morbidity, disfiguring lesions, and functional impairment, often leading to social stigma and poor quality of life (ā).
The global incidence of CBM is difficult to determine due to its non-notifiable status and the limited availability of data, which mainly consist of small case series or reports (). Although believed to have a similar overall burden to mycetoma, its geographic distribution and incidence in endemic regions remain poorly defined (, ).
CBM presents with a heterogeneous clinical picture, ranging from mild skin lesions at the site of fungal implantation to severe, disfiguring lesions (). All age groups can be affected; however, individuals engaged in soil-related occupations are at higher risk of morbidity. This disease affects primarily males (80%), typically presenting between 43 and 56 years of age. It most commonly affects the lower limbs (60%), with an average duration of 10.8 years before diagnosis (). Studies on CBM are generally limited. For instance, in Ethiopia, a retrospective study identified 12 CBM cases among 20 subcutaneous mycoses, with 75% male predominance and a median age of 44 years (). The prevalence is higher in tropical and subtropical regions, including Latin America, Africa, and Asia (). In resource-limited settings, underreporting, a lack of surveillance system, and barriers to care underestimate the true incidence, delay diagnosis, and hinder effective public health planning. Untreated CBM can result in debilitating tissue fibrosis, lymphedema, secondary bacterial infection, and squamous cell carcinoma (, ). This review focuses on the epidemiology, pathogenesis, diagnosis, treatment, and prognosis of CBM in marginalized populations to address knowledge gaps and provide a theoretical foundation for improving early case detection and treatment.
Brief historical context of chromoblastomycosis
The clinical picture of CBM was first described with documented cases in the early 20th century, with the initial report dating back to Brazil in 1914 (). Since then, understanding of the disease has greatly evolved, including identification of its etiologic fungi, pathological features, and treatment. The disease, formerly called chromomycosis in some regions. However, chromoblastomycosis is now the preferred term, as it reflects the distinctive presence of the so-called āchromoblasts,ā or muriform or sclerotic cells, in the infected tissues. These muriform or sclerotic cells are clusters of fungal cells and are pathognomonic for the diagnosis ().
In recognition of its epidemiological and public health significance, CBM was designated as a Neglected Tropical Disease (NTD) by the World Health Organization (WHO) in 2017 (). This inclusion underscores the diseaseās disproportionate impact on vulnerable populations and the need for enhanced surveillance, better diagnostic capabilities, and more effective treatment options. The designation also aligns CBM with similar chronic fungal NTDs, like mycetoma and paracoccidioidomycosis, reflecting shared challenges related to poverty, healthcare access, and persistent morbidity ().
Etiologic agents
CBM is primarily caused by melanized fungi, especially within the Herpotrichiellaceae family. According to available databases, common causative agents are Fonsecaea species (F. pedrosoi, F. erecta, F. nubica, and F. brasiliensis) and Cladophialophora species (C. carrionii and C. yegresii). Fonsecaea (especially F. pedrosoi) and Cladophialophora (C. carrionii) species are the most frequent causative agents worldwide (). Molecular tools have identified several rare or emerging agents, improving pathogen detection. These include Fonsecaea monophora, genetically distinct from F. pedrosoi and exhibiting clinical differences, and recently described Fonsecaea pugnacius, associated with disseminated disease (). Other rare agents include Exophiala species, causing systemic infections in immunocompetent children, and a non-sporulating Rhytidhysteron species, notable for its rare pathogenicity in humans (, ā).
Global burden of chromoblastomycosis
Epidemiology and risk factors
Melanized fungi are ubiquitous in tropical and subtropical environments, where CBM is most prevalent (). The two most common causative agents were F. pedrosoi (predominates in humid regions) and C. carrionii (common in semiarid climates). Sporadic cases have been reported in temperate zones and, rarely, following natural disasters in non-endemic areas (). The global burden of CBM is unknown since it is not a reportable disease, and incidence estimates vary by region. A CDC report indicates that reliable disease burden estimates are lacking due to the absence of national, regional, or global disease surveillance systems (). However, it is endemic in more than 80 countries across Latin America, sub-Saharan Africa (especially East Africa), and Asian countries (, ). To date (1914ā2023), approximately 7,850 confirmed cases have been reported globally in the literature, though the true burden is likely higher due to substantial underreporting and misdiagnosis, particularly in resource -limited settings (FigureĀ 1) (, ).
FigureĀ 1
Central and South America
This condition predominantly affects certain parts of America. In the Latin America, countries such as Brazil, Venezuela, the Dominican Republic, Mexico, Costa Rica, Colombia, and Cuba are commonly affected. Latin America is the most impacted region globally, accounting for approximately 50ā60% of all reported global CBM cases (approximately 4,247 cases) (, , , ).
Asia
Asia accounts for nearly one- fourth of all globally reported CBM cases, making it the third most commonly affected region after Latin America and Africa. The disease is endemic in more than 15 Asian countries, primarily in South, Southeast, and East Asia, where tropical and subtropical climates favor fungal persistence. To date, approximately 1,394 cases have been reported across the continent, with the highest burdens observed in China, Japan, India, and Sri Lanka (, , ).
Africa
In Africa, CBM prevalence is not uniformly distributed but rather concentrated in specific regions, contributing approximately more than one - fourth of all globally reported cases (). The disease is endemic in over 20 African countries, particularly in East, Central, and Southern Africa. To date (1914 ā 2020), an estimated 1,875 cases have been reported, with the highest burdens in Madagascar, followed by South Africa, Congo, and East African nations such as Ethiopia, Kenya, and Uganda (, , , ). In 2023, Madagascar reported an additional 113 clinical cases of CBM to the WHO, including 110 new cases, of which 81 were laboratory confirmed, and 3 recurrent cases ().
Ethiopia
In Ethiopia, skinārelated neglected tropical diseases, particularly CBM, are commonly encountered in outpatient settings. The country carries a hidden burden of CBM but lacks nationwide epidemiological studies. Current evidence is primarily limited to case reports and small hospitalābased studies. In 2023, a multicenter study found that 21 cases (14.7%) of subcutaneous mycoses cases were CBM, primarily affecting male rural agricultural workers, with Tigray being a regional hotspot (). Another retrospective review at ALERT Hospitalās dermatology clinic over five years identified 12 confirmed CBM cases from Oromia, Amhara, Addis Ababa, and the Southern region (). There were also another 14 cases of CBM reported in the global literature between 1947 and 2018 (, ). These studies indicate that CBM in Ethiopia disproportionately affects rural, agricultural populations and exhibits regional variation, highlighting the need for better diagnostics and reporting to determine the true incidence (TableĀ 1).
TableĀ 1
| Study (Year) | Study design & site(s) | Regions | No. of CBM cases | Notes |
|---|---|---|---|---|
| Enbiale etĀ al., 2023 () | Rapid assessment of subcutaneous mycoses in 13 referral hospitals (2018ā2022) | Tigray, Amhara and other regions fewer cases | 21 (14.7%) | Twoāthirds of CBM cases were from northern Ethiopia (Tigray + Amhara). |
| Abate etĀ al., 2021 () | Retrospective 5āyear review at ALERT Hospital, Addis Ababa (2015ā2019) | Oromia, Amhara, Addis Ababa, Southern region | 12 | Small hospitalābased series |
| Global reviews () | Reviews of endemic mycoses (1914ā2020) | Ethiopia recognized as endemic, but no regional prevalence estimates | 14 | Highlight underreporting and lack of surveillance data. |
Chromoblastomycosis cases in Ethiopia (1914ā2023): A regional overview of published cases.
Age
The disease typically affects individuals between 30 and 50 years old. It is uncommon in children exposed to the same environmental conditions as adults. The long incubation period, lasting years after inoculation, accounts for its rarity in children ().
Sex and race
Interestingly, CMB shows no clear racial predilection, though one study in Brazil reported a higher occurrence among older white male rural workers. The disease predominantly affects men (about 70% of cases), likely due to greater agricultural exposure and selfāinjury risk, with a possible protective role of female hormones ().
Risk factors
Regarding risk factors, a few studies indicate that the primary sources of infection are soil and plant materials, with the causative fungi living saprobically on leaves, thorns, seeds, and decaying wood. The risk of infection is strongly associated with cutaneous trauma during outdoor work or recreational activities, including agriculture, hunting, and ecotourism. In some endemic regions, CMB is considered an occupational disease, primarily affecting farm workers, gardeners, and others exposed to contaminated plant matter or soil (, , ).
Pathogenesis of chromoblastomycosis
The pathogenesis begins with the traumatic introduction of fungal elements into the skin from environmental sources. Once the fungus penetrates the skin, it triggers a chronic granulomatous lesion with fibrosis, progressive tissue proliferation, and formation of multiple microāabscesses, mediated by a dominant Tāhelper type 2 (Th2) immune response. Within the affected tissue, sclerotic bodies become embedded, giving rise to the characteristic polymorphic cutaneous lesion. Chronic tissue involvement can cause functional impairment and, rarely, malignant transformation. The pathogenesis involves both fungal adaptation and the hostās chronic inflammatory response, driving disease progression and morbidity (, ).
CBM is caused by a limited group of melanized fungi. These fungi possess several virulence factors that are likely to play a role in the disease development, including a unique dimorphism resulting in sclerotic body formation characterized by the presence of melanin in the cell wall, hydrophobicity, and strong cell adhesion (). Sclerotic bodies, also referred to as muriform cells, or Medlar bodies, are thickāwalled, brown, polyhedral structures that resist host immune defenses, retain the capacity for replication and dormancy, and thereby contribute to the chronicity and therapeutic recalcitrance of the infection ().
Fungal cell adhesion and hydrophobicity promote tissue attachment and muriform cell transition, while melanin protects against host immunity (). Host responses, mainly macrophages and cellāmediated immunity, induce granulomatous inflammation and microāabscesses, controlling fungal growth in immunocompetent individuals. Additionally, genetic factors may increase susceptibility, while hormonal influences in females are uncertain (). Understanding the pathogenesis of CBM requires integrating fungal biology, host immunity, and tissue pathology to address its chronic nature and therapeutic challenges.
Clinical manifestations
Clinical manifestations usually appear at the site of skin trauma, and the duration of illness ranges from a few weeks to months after inoculation (, ). Initially, the lesions usually present as solitary erythematous macules or papules, most commonly on exposed areas of the limbs, and are often asymptomatic or only mildly pruritic (). As disease progresses (lateāstage), the lesions may evolve into nodular, verrucous, tumorous, plaque, or cicatricial forms, sometimes exhibiting multiple morphologies simultaneously, and are often accompanied by pruritus, local pain, and characteristic black dots or a cayenne pepper appearance (FigureĀ 2) (). The infection spreads contiguously and occasionally via lymphatics, with clinical progression influenced by fungal virulence, lesion location, and host immunity (, ). In resourceālimited settings, patients often present with lateāstage disease due to a lack of awareness and limited access to advanced healthcare. This creates a delay in diagnosis, usually postpone effective therapy and increase the risk of complications.
FigureĀ 2
Diagnosis of chromoblastomycosis
Diagnosis of CBM remains challenging. It demands strong clinical suspicion because of its varied presentation, the nature of disease progression, and limited awareness among physicians (). It should be suspected in patients with persistent, slowāgrowing, verrucous lesions or those residing in or visiting tropical and subtropical regions. The appearance of cayenne pepper or small black dots on lesions suggests the diagnosis, but definitive confirmation requires identification of muriform or sclerotic bodies (Medlar bodies or copper pennies) in clinical samples via direct microscopy, histopathology, biopsies, or fine needle aspiration (, ). These pigmented, thickāwalled, round to polyhedral fungal cells with internal septations (muriform cells) are pathognomonic for diagnosis (FigureĀ 3). Histopathology typically reveals pseudoepitheliomatous hyperplasia, granulomatous inflammation, micro abscesses, and muriform cells (, ).
FigureĀ 3
In addition to that, dermoscopy enhances visualization of black dots, facilitating targeted sampling for fungal confirmation. Serology (ELISA or immunodiffusion) can detect antibodies for research purposes (). Diagnostic methods include:
KOH preparation: Detects muriform cells in black-dot scrapings.
Skin biopsy: An elliptical incisional or punch biopsy including epidermis, dermis, and subcutis allows histology to reveal muriform cells, hyperkeratosis, pseudoepitheliomatous hyperplasia, and pyogranulomatous inflammation.
Fungal culture: Confirms the genus via slowāgrowing, pigmented colonies on selective media.
Furthermore, molecular diagnosis plays a key role in CBM by enabling accurate speciesālevel identification of the causative fungi, improving diagnostic certainty, guiding antifungal selection based on known susceptibility patterns, and supporting prognostic assessment and treatment monitoring (ā).
Careful history and physical examination are crucial for early detection. Key supportive features include outdoor activity, prior trauma at the lesion site, extremity involvement, pruritus in advanced disease, and slow progression, though their absence does not rule out the diagnosis. In resourceālimited settings, history and direct microscopy of fine needle aspirates or biopsies can be used for diagnosis where advanced facilities are unavailable () (FigureĀ 4).
FigureĀ 4
Differential diagnosis
Chronic, polymorphic lesions can mimic viral, bacterial, protozoal, or fungal infections, as well as noninfectious dermatologic conditions. Demonstration of muriform cells on KOH or biopsy is diagnostic (TableĀ 2).
TableĀ 2
| Condition | Key clinical clues | How it differs from CBM | Preferred diagnostic test |
|---|---|---|---|
| Sporotrichosis | Nodular lesions along lymphatics | Less verrucous, more linear spread | Biopsy showing cigarāshaped yeast, Culture (gold standard) |
| Mycobacterium marinum | Papulonodular lesions on forearms, aquatic exposure | No sclerotic bodies, may show lymphatic spread | AFB stain, culture |
| Cutaneous Leishmaniasis | Chronic ulcers with raised edges, travel to endemic regions | Amastigotes present, usually ulcerative rather than verrucous | Giemsa smear/biopsy confirming amastigotes, PCR |
| Cutaneous Blastomycosis | Verrucous or ulcerated lesions often with systemic symptoms | Larger, broadābased budding yeast, pulmonary signs | Biopsy showing broadābased budding yeast, urine antigen |
| Cutaneous TB | Warty plaques, prior TB exposure or trauma | Granulomas and AFB, no sclerotic bodies | Biopsy showing granuloma and AFB stain, culture or PCR |
| Verrucous carcinoma | Exophytic, irregular, friable warty mass | Neoplastic architecture, no fungal elements | Biopsy showing wellādifferentiated SCC |
| Mycetoma | Painless nodules, draining sinuses and grains | Sinus tracts with colored granules, not verrucous | Direct microscopy of grains, culture, biopsy |
Top differential diagnoses of chromoblastomycosis (with key diagnostic tests).
Treatment
Treatment of CBM poses significant challenges due to its nonāmandatory reporting status, prolonged use of antifungal drugs, and frequently suboptimal therapeutic responses. No randomized controlled trials or consensus guidelines currently exist for the treatment of CBM, which highlights a significant evidence gap. Consequently, current treatment strategies are primarily informed by case reports, case series, expert consensus, and uncontrolled studies, with treatment decisions guided by the severity and extent of the disease. Disease severity is categorized as mild (solitary lesion <5 cm), moderate (single or multiple lesions <15 cm confined to one or two adjacent areas), or severe (extensive involvement of adjacent or nonadjacent areas). Overall, pharmacotherapy remains the cornerstone of treatment, whereas surgical intervention may be appropriate for selected cases with mild disease (, ).
Surgical therapy
Available evidence indicates that surgical excision is the preferred treatment for mild, wellādefined lesions, with excision extending into the subācutis and including margins of at least 0.5 cm, combined with antifungal therapy to reduce recurrence and treat residual infection. Dermoscopy may assist in delineating surgical margins, and histopathologic confirmation of clear margins is ideal. Surgery is generally not recommended for moderate to severe disease due to poorly defined lesion borders and the risk of local fungal implantation (, ).
Medical therapy
Medical therapy remains the most fundamental modality for the treatment of this condition. Systemic antifungal therapy should be initiated in patients presenting with moderate to severe disease, extensive involvement, or failure of topical therapy. The primary recommended agents are terbinafine and itraconazole, both of which have demonstrated robust efficacy in the treatment of CBM. The selection of therapy should consider the infection site, comorbidities, drug interactions, and hepatic function status.
Monotherapy
Itraconazole
A triazole antifungal, is a key treatment option for CBM, particularly in cases when terbinafine is contraindicated. Itraconazole is typically the firstāline choice, but terbinafine, and voriconazole have also been used successfully (). Recommended dosing is 200ā400 mg/day for 8ā36 months, with cure rates varying widely from 15% to 80% due to slow clinical response. Pulsed therapy (400 mg/day for one week per month) may also be effective (, ).
Terbinafine
Inhibits squalene epoxidase, causing ergosterol depletion and disruption of the fungal cell membrane. It is generally preferred as firstāline therapy due to its high mycologic cure rates, favorable safety profile, better absorption, and shorter treatment duration. Administered at 250ā500 mg/day, terbinafine has achieved 66% complete healing in patients with Fonsecaea pedrosoi infections over 12 months. Additional advantages include fewer drug interactions and potential antiāfibrotic effects (, ).
Other agents
Posaconazole and voriconazole have demonstrated efficacy in refractory cases, while, flucytosine and amphotericin B, are largely abandoned due to practical limitations, including the need for combination therapy, requirements for therapeutic drug monitoring, toxicity concerns, and intravenous administration, respectively ().
Combination therapy
Recommended for severe or refractory disease. According to the CDC and multiple studies, itraconazole with terbinafine (alternate weeks) or itraconazole with flucytosine has been used in clinical practice for such cases (58). Additionally, physical interventions (cryotherapy, heat therapy, laser or photodynamic therapy) may enhance outcomes in persistent or extensive disease (). Additional evidence from Brazil indicates that adjunctive use of topical imiquimod, reported mainly in small case series and case reports have demonstrated enhanced local inflammatory responses and lesion regression when used in combination with systemic antifungal therapy for chronic subcutaneous mycoses, particularly CBM (59ā61).
Refractory cases
Patients who fail standard oral therapy may benefit from combination antifungal regimens or adjunctive physical therapy. Alternating itraconazole and terbinafine or itraconazole plus flucytosine is used. Adjunctive physical interventions can increase cure rates (58).
Adjunctive physical therapies
Physical therapy modalities play an important adjuvant role in treatment, such as cryotherapy, heat therapy, and lightābased therapies (62, 63).
Complications of chromoblastomycosis
Chronic CBM can cause disabling complications such as tissue fibrosis, lymphedema, secondary infections, and, rarely, malignant transformation. Interestingly, malignant transformation to squamous cell carcinoma is a rare but recognized complication of CBM, reported in approximately 1% of cases in large series from Madagascar. Prolonged disease duration spanning several decades, chronic inflammation, repeated tissue damage, and fibrosis are considered potential risk factors contributing to malignant degeneration (64, 65) (TableĀ 3).
TableĀ 3
| Complication | Description |
|---|---|
| Fibrosis with lymphedema/lymph stasis | Progressive fibrosis leading to swelling, stasis, or elephantiasisālike changes |
| Joint immobility / ectropion | Functional impairment depending on lesion site |
| Secondary bacterial infections | Often in advanced verrucous/ulcerated lesions, may progress to osteomyelitis |
| Osteomyelitis | Extension of secondary bacterial infection into bone |
| Malignant transformation (SCC) | Risk in longāstanding lesions with lymphedema or recurrent infections, onset 5ā36 years |
| Deep/internal organ involvement | Extremely rare, unlike sporotrichosis or mycetoma |
The summary of chromoblastomycosis complications.
Postātreatment assessment and followāup
The postātreatment phase of CBM assessment is the most critical period for ensuring longāterm success of therapy and preventing relapse. Following active treatment, patients need systematic evaluation to confirm clinical and mycological cure (66). To achieve lasting remission and prevent recurrence, sustained surveillance, laboratory confirmation, and preventive care are crucial (, 67). Cure is established through clinical and mycological criteria (68), the clinical criteria are as follows:
Complete healing of all lesions.
Flattening or reāepithelialization of the lesions, except for residual atrophic scars or fibrotic scarring.
No active borders.
Resolution of pruritus, local pain, or discharge.
Stable postātreatment fibrosis without progression or new lesions for at least 3ā4 months after treatment.
Mycological cure
A complete fungal eradication from tissue, confirmed by negative laboratory findings (KOH examination, tissue culture, and histology) sustained for at least 3ā4 months during followāup.
Treatment failure
Persistent active lesions with positive microscopy and culture.
More importantly, clinical remission does not guarantee mycologic cure, as fungal elements can persist in tissue. Nonviable fungal elements on histopathology, in the absence of positive culture and microscopy, do not necessarily indicate treatment failure.
Furthermore, longāterm followāup is recommended for ā„2 years with reassessments every 3ā4 months, including physical examination, mycologic testing, and skin biopsy to detect relapse or incomplete eradication (67, 68). Nevertheless, in resourceālimited settings, the followāup is often inconsistent and leads to increased recurrence and chronic morbidity. Therefore, strong patient counseling is the rule.
Prognosis
The prognosis for CBM is generally favorable and largely depends on the stage and extent of the disease. In cases with small, localized lesions, the outlook is good, however, in advanced stages involving extensive areas, complete cure becomes challenging, although the condition can often be effectively controlled. Mortality from CBM is rare, but morbidity correlates directly with the extent of the disease. In the early papule or nodule stage, the infection is typically asymptomatic. As nodules coalesce into large plaques that may affect an entire limb, complications such as disabling tissue fibrosis, lymphedema, secondary bacterial infections, and rarely, malignant transformation can develop (, ).
Prevention
Preventing CBM relies on minimizing cutaneous trauma in the most vulnerable segment of the population. Individuals involved in outdoor occupations or recreational activities should use protective clothing, gloves, and closedātoe shoes to limit contact with contaminated soil, plant debris, and thorns. Immediate cleansing and disinfection of cuts, punctures, or abrasions, along with early medical evaluation of suspicious lesions, are important to reduce the risk of infection. Prevention remains challenging due to the occupational nature of the disease, as it mainly affects individuals performing soilārelated work. Early diagnosis is crucial to mitigate the complications (, ). Public health education plays a critical role in prevention, emphasizing awareness of highārisk activities, proper wound care, and the importance of seeking timely treatment.
Current status of chromoblastomycosis and barriers to service delivery in Ethiopia
The delivery of CBM services in Ethiopia remains limited and fragmented, reflecting broader health system challenges. As a neglected fungal disease, CBM suffers from low awareness among both healthcare workers and communities, resulting in frequent misdiagnosis and prolonged morbidity. Cases of CBM and other NTDs are commonly encountered in outpatient settings, particularly among patients from rural and agricultural areas where access to dermatology services and diagnostic facilities is scarce. Consequently, many patients receive delayed or inadequate treatment (69).
Several health system barriers hinder effective CBM service delivery. These include poor integration of CBM into primary healthcare, a shortage of trained personnel, and limited availability of diagnostic tools such as microscopy and histopathology at peripheral health facilities. Access to effective antifungal therapy is inconsistent, with high costs and unreliable supply chains further restricting care. In addition, weak surveillance and reporting systems lead to underestimation of the disease burden, impeding informed planning and resource allocation for NTDs. Limited domestic funding, minimal research capacity, and low community awareness further contribute to delays in diagnosis, treatment, and longāterm management of CBM (70).
Governance and policy challenges in Ethiopia
The governance and policy environment in Ethiopia poses additional challenges to the prevention, diagnosis, and management of CBM and other neglected fungal diseases. Despite the presence of formal health governance structures, gaps persist in leadership, coordination, and implementation capacity across administrative levels. Fragmentation among national, regional, and district health authorities, limited multisectoral engagement, and weak accountability mechanisms impede effective program implementation, particularly for underārecognized conditions. Inconsistent coordination, uneven communication, and policy execution bottlenecks further weaken health governance and oversight frameworks (71).
Furthermore, underdeveloped surveillance and routine health information systems for conditions not systematically tracked such as subcutaneous mycoses, significantly limit progress. Weak reporting mechanisms and persistent data gaps reduce the visibility of CBM in official health records, constraining policymakersā ability to accurately estimate disease burden and prioritize appropriate public health responses (72).
Policy gaps in Ethiopia
Although CBM and other subcutaneous mycoses are endemic in Ethiopia, they remain largely absent from national disease control priorities due to limited disease mapping and inadequate surveillance data (). National health policies predominantly focus on highāburden communicable diseases, maternal and child health, and selected priority neglected tropical diseases, resulting in the exclusion of deep fungal infections.
While existing health sector strategies provide a framework for integrating disease control into primary healthcare, weak governance structures, insufficient financing, logistical constraints, and underdeveloped health information systems limit the effective mainstreaming of nonāpriority diseases. These gaps perpetuate delayed recognition, inadequate service delivery, and limited policy attention for CBM in Ethiopia.
Recommendations and way forward
Improving service delivery for skinārelated neglected tropical diseases in Ethiopia requires addressing critical gaps in awareness, diagnosis, treatment access, and research. Integrating CBM and other neglected fungal skin diseases into primary healthcare and dermatology services is essential for early detection, particularly in rural and agricultural settings.
Capacity building through continuous training of healthcare workers or one health principle regular lecture on clinical recognition, diagnosis, and longāterm management is equally important. Expanding access to basic diagnostic services such as microscopy and histopathology peripheral laboratories would reduce diagnostic delays and mismanagement. Ensuring affordable access to essential antifungal medicines through inclusion in the national essential medicines list, the appointment of dedicated program managers, implementation of national control programs or mass drug administration (MDA) strategies, and the establishment of clear referral pathways for complex cases is also critical.
Sustained progress will require increased domestic financing, stronger government ownership of neglected fungal disease programs, and enhanced community awareness to promote early careāseeking and reduce stigma. Strengthening local research and surveillance systems is necessary to generate contextāspecific evidence, inform policy, and support longāterm control of CBM in Ethiopia.
Conclusion
CBM is a longāstanding, skinārelated neglected tropical disease associated with substantial morbidity, social stigma, and reduced quality of life. Its global prevalence varies across regions, with higher rates reported in specific endemic areas, however, limited clinical recognition and weak public health surveillance likely result in significant underestimation of the true disease burden. Early diagnosis, accurate fungal identification, and prolonged antifungal therapy are essential to prevent complications and improve outcomes.
Early case detection is particularly critical in resourceālimited settings. Strengthened surveillance systems and molecular epidemiological studies are needed to better define disease distribution and burden. Investment in healthcare infrastructure, prevention strategies, and community engagement, alongside multidisciplinary research in endemic countries, is vital to address existing knowledge gaps and reduce CBMārelated morbidity.
Future directions
Future efforts in CMB should prioritize rapid, affordable diagnostics, particularly molecular tools that enable early, speciesālevel identification. Wellādesigned clinical studies are needed to rigorously evaluate multimodal therapy, including optimized antifungal combinations and adjuncts like cryotherapy, phototherapy, and immunomodulators. Advances in virulence profiling and antifungal susceptibility testing will help refine therapeutic strategies, while improved surveillance and implementation models are essential to address the disproportionate burden in resourceālimited settings. Together, these directions offer a pathway toward more effective, accessible, and durable control of this neglected mycosis. The One Health approach may represent an important way forward for future policy and programmatic action in addressing rare conditions.
Statements
Author contributions
AL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing ā original draft, Writing ā review & editing. AE: Conceptualization, Data curation, Resources, Validation, Visualization, Writing ā original draft, Writing ā review & editing. JG: Conceptualization, Data curation, Resources, Validation, Visualization, Writing ā original draft, Writing ā review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
SonawaneGPansareKPatilCMahajanSSonawaneD. Chromoblastomycosis: an update on pathogenesis, clinical features, and diagnosis. Insights Pharmatech. (2025) 1:2ā14. Available online at: https://amepurvapub.com/index.php/InsightsPharmatech/article/view/3.
2
Queiroz-TellesFEsterrePPerez-BlancoMVitaleRGGuedes SalgadoCBonifazA. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Medical Mycology. (2009) 47:3ā15. doi:Ā 10.1080/13693780802538001
3
KrzyÅciakPMPindycka-PiaszczyÅskaMPiaszczyÅskiM. Review paper Chromoblastomycosis. Advances in Dermatology and Allergology. (2014) 5:310ā21. doi:Ā 10.5114/pdia.2014.40949
4
de BritoACBittencourt M deJS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. Bras Dermatol. (2018) 93:495. doi:Ā 10.1590/abd1806-4841.20187321
5
GuevaraASiqueiraNPNeryAFCavalcanteLRDSHagenFHahnRC. Chromoblastomycosis in Latin America and the Caribbean: Epidemiology over the past 50 years. Med Mycol. (2022) 60. doi:Ā 10.1093/mmy/myab062
6
AgarwalRSinghGGhoshAVermaKKPandeyMXessI. Chromoblastomycosis in India: review of 169 cases. PloS Negl Trop Dis. (2017) 11:e0005534. doi:Ā 10.1371/journal.pntd.0005534
7
SantosDWCLde Azevedo C de MP e.SVicenteVAQueirozāTellesFRodriguesAMde HoogGSet al. The global burden of chromoblastomycosis. PloS Negl Trop Dis. (2021) 15:e0009611. doi:Ā 10.1371/journal.pntd.0009611
8
TuckwellWYesudianPDChandlerD. Chromoblastomycosis: a contemporary review of a neglected disease. Clin Exp Dermatol. (2025). doi:Ā 10.1093/ced/llaf201
9
QueirozāTellesF. Chromoblastomycosis: A neglected tropical disease. Rev Inst Med Trop Sao Paulo. (2015) :57:46ā50. doi:Ā 10.1590/S0036-46652015000700009
10
AssefaWSinatayehuRSendekuMADiresM. Chromoblastomycosis: delayed diagnosis with extensive cutaneous lesions. Int J Infect Dis. (2023) 131:50ā2. Available online at: https://www.ijidonline.com/action/showFullText?pii=S1201971223001194.
11
MuglestonBJUsatineRPRosenT. Wide morphologic variability of chromoblastomycosis in the western hemisphere. Skinmed. (2016) 14:423ā7. Available online at: https://pubmed.ncbi.nlm.nih.gov/28031127/.
12
QueirozāTellesFEsterrePPerezāBlancoMVitaleRSalgadoCGBonifazA. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. (2009) 47:3ā15. doi:Ā 10.1080/13693780802538001
13
PasseroLFDCavalloneINBeldaW. Reviewing the etiologic agents, microbeāhost relationship, immune response, diagnosis, and treatment in chromoblastomycosis. J Immunol Res. (2021) 2021:9742832. doi:Ā 10.1155/2021/9742832
14
SmithDJQueirozāTellesFRabenjaFRHayRBonifazAGrijsenMLet al. A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group. PloS Negl Trop Dis. (2024) 18:e0012562. doi:Ā 10.1371/journal.pntd.0012562
15
RasamoelinaTMaubonDAndrianarisonMRanaivoISendrasoaFRakotozandrindrainyNet al. Endemic chromoblastomycosis caused predominantly by fonsecaea nubica, Madagascar1. Emerg Infect Dis. (2020) 26:1201ā11. doi:Ā 10.3201/eid2606.191498
16
SanchezāDiazMde MayoloNARamosCChinchaOBustamanteB. Chromoblastomycosis in Peru: a retrospective review of 13 cases. BMC Infect Dis. (2025) 25:1ā7. doi:Ā 10.1186/s12879-025-11475-4
17
Lacaz C daSPortoEMartinsJEC. Micologia medica: fungos actinomicetos e algas de interesse medico. Journal of the Institute of Tropical Medicine of SĆ£o Paulo. Edicao revisada e aumentada (1991).
18
On the priority of description of chromomycosis. | Read by QxMD. (2025). Available online at: https://read.qxmd.com/read/3320744/on-the-priority-of-description-of-chromomycosis?redirected=slug.
19
WHO. Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases: executive summary. World Health Organization (2017).
20
MedlarEM. A cutaneous Infection caused by a new Fungus, Phialophora Verrucosa, with a Study of the Fungus ā PubMed. J Med Res. (1915) 32:507ā22.9. Available online at: https://pmc.ncbi.nlm.nih.gov/articles/PMC2094505/.
21
KurienGSugumarKSatheNCChandranV. Chromoblastomycosis. Pract Otol. (2024) 52:715ā26. Available online at: https://pubmed.ncbi.nlm.nih.gov/29261968/.
22
KurienGSugumarKSatheNCChandranV. Chromoblastomycosis ā statPearls ā NCBI bookshelf. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. (2025). Available online at: https://www.ncbi.nlm.nih.gov/books/NBK470253/.
23
MartĆnezECValeirónCRYegresFReyesR. The goat: approach to an animal model in human chromomycosis. Invest Clin. (2005) 46:131ā8. Available online at: https://europepmc.org/article/MED/16001745.
24
CalvoEPastorFJSalasVMayayoECapillaJGuarroJ. Histopathology and antifungal treatment of experimental murine chromoblastomycosis caused by Cladophialophora carrionii. J Antimicrob Chemother. (2012) 67:666ā70. doi:Ā 10.1093/jac/dkr537
25
KondoMHirumaMNishiokaYMayuzumiNMochidaKIkedaSet al. A case of chromomycosis caused by Fonsecaea pedrosoi and a review of reported cases of dematiaceous fungal infection in Japan. Mycoses. (2005) 48:221ā5. doi:Ā 10.1111/j.1439-0507.2005.01089.x
26
ParkSGOhSHSuhSBLeeKHChungKY. A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: Treatment with a combination of amphotericin B and 5āflucytosine. Br J Dermatol. (2005) 152:560ā4. doi:Ā 10.1111/j.1365-2133.2005.06424.x
27
Chromomycosis in Japan. | Read by QxMD. (2025). Available online at: https://read.qxmd.com/read/7316574/chromomycosis-in-Japan?redirected=slug.
28
[Chromomycosis in Finland. The possible role of the Finnish sauna in its spreading]. | Read by QxMD. (2025). Available online at: https://read.qxmd.com/read/5995093/chromomycosis-in-Finland-the-possible-role-of-the-finnish-sauna-in-its-spreading?redirected=slug.
29
Clinical Overview of Chromoblastomycosis | Chromoblastomycosis | CDC. (2025). Available online at: https://www.cdc.gov/chromoblastomycosis/hcp/clinical-overview/index.html.
30
WHO. Global report on neglected tropical diseases: Protozoan infections. World Health Organization (2025). Available online at: https://www.who.int/teams/control-of-neglected-tropical-diseases/global-report-on-neglected-tropical-diseases-2025.
31
Chromoblastomycosis. (2025). Available online at: https://www.who.int/news-room/fact-sheets/detail/chromoblastomycosis.
32
MinottoRBernardiCDVMallmannLFEdelweissMIAScrofernekerML. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol. (2001) 44:585ā92. doi:Ā 10.1067/mjd.2001.112220
33
EnbialeWBekeleAManayeNSeifeFKebedeZGebremeskelFet al. Subcutaneous mycoses: Endemic but neglected among the Neglected Tropical Diseases in Ethiopia. PloS Negl Trop Dis. (2023) 17:e0011363. doi:Ā 10.1371/journal.pntd.0011363
34
AbateDAAyeleMHMohammedAB. Subcutaneous mycoses in Ethiopia: a retrospective study in a single dermatology center. Trans R Soc Trop Med Hyg. (2021) 115:1468ā70. doi:Ā 10.1093/trstmh/trab080
35
OlafssonJLindtjornBBeiskeK. Chromomycosis: a report of three cases from Ethiopia. Ethiop Medical Journal. (1981) 19:91ā6. doi:Ā 10.5555/19822902229
36
GimbelDCLegesseTB. Dermatopathology practice in Ethiopia. meridian.allenpress.comDC Gimbel, TB LegesseArchives of Pathology and Laboratory Medicine, 2013ā¢meridian.allenpress.com (2013). Available online at: https://meridian.allenpress.com/aplm/article-abstract/137/6/798/132540.
37
Medical mycology : the pathogenic fungi and the pathogenic actinomycetes : Rippon, John Willard : Free Download, Borrow, and Streaming : Internet Archive. (2025). Available online at: https://archive.org/details/medicalmycologyp0000ripp/page/n9/mode/2up.
38
QueirozāTellesFde HoogSSantosDWCLSalgadoCGVicenteVABonifazAet al. Chromoblastomycosis. Clin Microbiol Rev. (2017) 30:233ā76. doi:Ā 10.1128/CMR.00032-16
39
WHO. Chromoblastomycosis. (2023).
40
PradhanSVTalwarOPGhoshASwamiRMShiva RajKCGuptaS. Chromoblastomycosis in Nepal: a study of 13 cases. Indian J Dermatol Venereol Leprol. (2007) 73:176ā8. doi:Ā 10.4103/0378-6323.32741
41
LangfelderKStreibelMJahnBHaaseGBrakhageAA. Biosynthesis of fungal melanins and their importance for human pathogenic fungi. Fungal Genet Biol. (2003) 38:143ā58. doi:Ā 10.1016/S1087-1845(02)00526-1
42
Pathogenesis and Immunology of Chromoblastomycosis: A review ā Yahoo Search Results. (2025). Available online at: https://search.yahoo.com/search?fr=mcafee&type=E211US1358G0&p=Pathogenesis+and+Immunology+of+Chromoblastomycosis%3A+A+review.
43
NosanchukJDCasadevallA. The contribution of melanin to microbial pathogenesis. Cell Microbiol. (2003) 5:203ā23. doi:Ā 10.1046/j.1462-5814.2003.00268.x
44
DokicYVerstovsekGRosenT. Chromoblastomycosis presenting as a solitary lesion in a nonāendemic region. Cureus. (2023) 15:e49791. doi:Ā 10.7759/cureus.49791
45
BatresEWolfJEJrRudolphAHKnoxJM. Transepithelial elimination of cutaneous chromomycosis. Arch Dermatology. (1978) 114:1231ā2. doi:Ā 10.1001/archderm.1978.01640200083027
46
BonifazACarrascoāGerardESaĆŗlA. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. (2001) 44:1ā7. doi:Ā 10.1046/j.1439-0507.2001.00613.x
47
SunJNajafzadehMJGerrits van den EndeAHGVicenteVAFengPXiLet al. Molecular characterization of pathogenic members of the genus Fonsecaea using multilocus analysis. PloS One. (2012) 7. doi:Ā 10.1371/annotation/8fef18d2-c01c-4f66-9b75-ecbfac5c82a5
48
SunJNajafzadehMJGerrits van den EndeAHGVicenteVAFengPXiLet al. Molecular characterization of pathogenic members of the genus Fonsecaea using multilocus analysis. PLoS One. (2012) 7:e41512. doi:Ā 10.1371/journal.pone.0041512
49
NajafzadehMJGerrits van den EndeAHGVicenteVADolatabadiSSunJde HoogGS. Identification of chromoblastomycosis agents by PCR based reverse line blot (PCRāRLB) hybridization assay. Microb Pathog. (2018) 125:43ā7. Available online at: https://www.sciencedirect.com/science/article/abs/pii/S0882401018313834.
50
BorgesJREdaYVMIanhezMGarciaāZapataMTA. DIAGNOSIS OF CHROMOBLASTOMYCOSIS: AN HISTORICAL REVIEW. J Trop Pathol. (2022) 51:97ā115. doi:Ā 10.5216/rpt.v51i2.71026
51
RanawakaRR. Treatment of chromoblastomycosis with a combination of debulking surgery, intralesional amphotericin B, and oral terbinafine. Int J Dermatol. (2021) 60:1040ā1. doi:Ā 10.1111/ijd.15567
52
PreciadoMMAlmeidaJDDRomoEMLópezAPNavarro L de laT. Successful treatment of a case of extense verrucous chromoblastomychosis with surgical exeresis associated with the use of ketoconazole. Rev Cubana Med Trop. (2005) 57:226ā9. Available online at: https://pubmed.ncbi.nlm.nih.gov/17969280/.
53
SmithDJMelhemMSCDirvenJde Azevedo CMP e.SMarquesSGde Souza LimaBJFet al. Establishment of epidemiological cutoff values for Fonsecaea pedrosoi, the primary etiologic agent of chromoblastomycosis, and eight antifungal medications. J Clin Microbiol. (2025) 63. doi:Ā 10.1128/jcm.01903-24?download=true
54
QueirozāTellesFPurimKSFillusJNBordignonGFLameiraRPVan CutsemJet al. ITRACONAZOLE IN THE TREAMENT OF CHROMOBLASTOMYCOSIS DUE TO FONSECAEA PEDROSOI. Int J Dermatol. (1992) 31:805ā12. doi:Ā 10.1111/j.1365-4362.1992.tb04252.x
55
BlancoMPYegresFYegresNRde HumbriaLHernĆ”ndezRZeppenfeldtG. Itraconazole: Efficacy in chromomycosis caused by Cladosporium carrionii. Venezuela: Venezuelan Society of Medical, Surgical and Aesthetic Dermatology (1994) 32:13ā16.
56
EsterrePInzanCKRamarcelERAndriantsimahavandyARatsioharanaMPecarrereJLet al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. (1996) 134:33ā6. doi:Ā 10.1111/j.1365-2133.1996.tb15658.x
57
EsterrePInzanCKRatsioharanaMAndriantsimahavandyARaharisoloCRandrianiainaEet al. A multicentre trial of terbinafine in patients with chromoblastomycosis: Effect on clinical and biological criteria. J Dermatol Treat. (1998) 9:S29ā34. doi:Ā 10.3109/09546639809160714
58
GuptaAKTabordaPRSanzovoAD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. (2002) 40:529ā34. doi:Ā 10.1080/mmy.40.5.529.534
59
BeldaWCasolatoATSLuppiJBPasseroLFD. Managing chromoblastomycosis with acitretin plus imiquimod: A case report on the improvement of cutaneous lesions and reduction of the treatment time. J Dermatol. (2021) 48:1612ā5. doi:Ā 10.1111/1346-8138.16101
60
ZhengJLiuSXieZChenYXiLLiuHet al. Successful management of chromoblastomycosis utilizing conventional antifungal agents and imiquimod therapy. Ann Clin Microbiol Antimicrob. (2024) 23. doi:Ā 10.1186/s12941-024-00718-y
61
HuangXWXuMNDaiSQZengKLiL. Case report: shortāterm application of topical imiquimod is practical for chromoblastomycosis. Am J Trop Med Hyg. (2021) 105:1696ā7. doi:Ā 10.4269/ajtmh.21-0735
62
QueirozāTellesFde C L SantosDW. Challenges in the therapy of chromoblastomycosis. Mycopathologia. (2013) 175:477ā88. doi:Ā 10.1007/s11046-013-9648-x
63
LusianaPrayogoRLRihatmadjaRWidatySMenaldiSElizaet al. Heat therapy as an Excellent Adjuvant Treatment for Severe Chromoblastomycosis: A Case Report. In: Proceedings of the 23rd Regional Conference of Dermatology (RCD 2018). Porto, Portugal: SCITEPRESS ā Science and Technology Publications (2021) p. 406ā10. doi:Ā 10.5220/0008158504060410
64
JamilALeeYYThevarajahS. Invasive squamous cell carcinoma arising from chromoblastomycosis. Med Mycol. (2012) 50:99ā102. doi:Ā 10.3109/13693786.2011.571295
65
NaoliIMirandaSMiqueletoJSantoroBHelenoCCarvalhoCet al. Malignant Transformation under Longāstanding Chromomycosis Lesion Annals of Case Reports Case Report. Brazil (2024). doi:Ā 10.29011/2574-7754.101858.
66
BonifazATiradoāSĆ”nchezAGordilloL. Chromoblastomycosis. Cham (Switzerland): Springer (2024). pp. 99ā108. doi:Ā 10.1007/978-3-031-57836-6_12.
67
TorresāGuerreroEIsaāIsaRIsaMArenasR. Chromoblastomycosis. Clin Dermatol. (2012) 30:403ā8. Available online at: https://www.sciencedirect.com/science/article/abs/pii/S0738081X11002902?via%3Dihub.
68
QueirozāTellesFNucciMColomboALTobónARestrepoA. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol. (2011) 49:225ā36. doi:Ā 10.3109/13693786.2010.539631
69
Chromoblastomycosis. (2025). Available online at: https://www.who.int/news-room/fact-sheets/detail/chromoblastomycosis?utm_source=chatgpt.com.
70
SemahegnAManyazewalTGetachewEFekaduBAssefaEKassaMet al. Burden of neglected tropical diseases and access to medicine and diagnostics in Ethiopia: a scoping review. Syst Rev. (2023) 12. doi:Ā 10.1186/s13643-023-02302-5
71
AtnafuATeshaleGDellieEParkYS. Exploring health system challenges and gaps for crisis response in Ethiopia: a scoping review of publications and reports from 2020ā2024. BMC Health Serv Res. (2025) 25:928ā. doi:Ā 10.1186/s12913-025-13084-y
72
Home | ESPEN. (2025). Available online at: https://espen.afro.who.int/.
Summary
Keywords
chromoblastomycosis, epidemiology, diagnosis, treatment, prognosis, ethiopia
Citation
Lamessa A, Ejeta A and Gemechu J (2026) Chromoblastomycosis in resource-limited settings: a review. Front. Trop. Dis. 7:1772834. doi: 10.3389/fitd.2026.1772834
Received
21 December 2025
Revised
25 January 2026
Accepted
28 January 2026
Published
19 February 2026
Volume
7 - 2026
Edited by
Emmanuel Siddig, University of Khartoum, Sudan
Reviewed by
Sunny Doodu Mante, African Filariasis Morbidity Project, Ghana
Roderick Hay, Kingās College London, United Kingdom
Updates
Copyright
Ā© 2026 Lamessa, Ejeta and Gemechu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adugna Lamessa, adgnalem@gmail.com
ORCID: Adugna Lamessa, orcid.org/0000-0003-0753-3339
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.